Extremely low frequency-modulated static magnetic fields to treat cancer: A pilot study on patients with advanced neoplasm to assess safety and acute toxicity

Results of a toxicity pilot human study approved by the competent ethical Committee are reported. Eleven patients with heavily pre‐treated advanced cancer were enrolled in a pilot study with different schedules of time exposure to static magnetic fields (MF), amplitude modulated by ELF. An area incl...

Full description

Saved in:
Bibliographic Details
Published in:Bioelectromagnetics 2004-12, Vol.25 (8), p.563-571
Main Authors: Ronchetto, Flavio, Barone, Domenico, Cintorino, Marcella, Berardelli, Michele, Lissolo, Silvana, Orlassino, Renzo, Ossola, Piero, Tofani, Santi
Format: Article
Language:English
Subjects:
cancer
Dose Fractionation
Dose-Response Relationship, Radiation
Electromagnetic Fields
ELF field
Female
Humans
Male
Neoplasms - diagnosis
Neoplasms - radiotherapy
Pilot Projects
pilot study
Radiation Injuries - etiology
Radiation Injuries - prevention & control
Radiation Protection - methods
Radiotherapy Dosage
Risk Assessment - methods
Risk Factors
safety
static field
toxicity
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Results of a toxicity pilot human study approved by the competent ethical Committee are reported. Eleven patients with heavily pre‐treated advanced cancer were enrolled in a pilot study with different schedules of time exposure to static magnetic fields (MF), amplitude modulated by ELF. An area including the neck, thoracic and abdomen was MF exposed daily, 5 days/week for 4 weeks according to two different schedules: 20 min daily (4 patients) and 70 min daily (7 patients). ECOG performance status was 1 (2 patients), 2 (8 patients), 3 (1 patient). Toxicity was assessed according to WHO criteria. ECG, Chest X‐ray, physical examination, blood cell count and complete blood chemistry were performed before and at the end of the treatment. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevation (grade 2 toxicity) in 1 patient and microscopic urinary abnormalities in 5 patients were the only negative effects observed. We conclude that MF can be safely administrated according to the MF exposure schedules. Bioelectromagnetics 25:563–571, 2004. © 2004 Wiley‐Liss, Inc.
ISSN:0197-8462
1521-186X
DOI:10.1002/bem.20029